Docoh
Loading...

TMO Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Its Mission is to enable our customers to make the world healthier, cleaner and safer. Whether the customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, the company is here to support them. Its global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Company profile

Ticker
TMO
Exchange
CEO
Marc Casper
Employees
Incorporated
Location
Fiscal year end
Former names
THERMO ELECTRON CORP
SEC CIK
Subsidiaries
Thermo Fisher Scientific Operating Company LLC • Thermo Fisher Scientific Senior Financing LLC • Thermo Fisher Scientific (DE) Holding S.a.r.l. • Laboratory Management Systems, Inc. • Thermo Fisher Scientific Peru S.R.L. • Thermo Fisher Scientific Malaysia Sdn. Bhd. • Thermo Fisher Scientific (Barbados) Holding, Limited • Fisher Clinical Logistics LLC • Fisher Clinical Services (Suzhou) Co., Ltd. • Fisher Clinical Services Limited Liability Company ...
IRS number
42209186

TMO stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

6 Aug 21
28 Sep 21
31 Dec 21
Quarter (USD)
Jul 21 Apr 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
27 Aug 21 Casper Marc N Common Stock Other Acquire J Yes No 0 89,155 0 89,155
27 Aug 21 Casper Marc N Common Stock Other Dispose J Yes No 0 34,825 0 0
27 Aug 21 Casper Marc N Common Stock Other Dispose J Yes No 0 54,330 0 0
27 Aug 21 Casper Marc N Common Stock Payment of exercise Dispose F No No 548.51 2,528 1.39M 182,174.53
27 Aug 21 Boxer Michael A Common Stock Payment of exercise Dispose F No No 548.51 160 87.76K 10,918
27 Aug 21 Joseph R. Holmes Common Stock Payment of exercise Dispose F No No 548.51 16 8.78K 851
27 Aug 21 Michel Lagarde Common Stock Payment of exercise Dispose F No No 548.51 293 160.71K 16,879.205
27 Aug 21 Mark Stevenson Common Stock Payment of exercise Dispose F No No 548.51 1,158 635.17K 59,256
26 Aug 21 Casper Marc N Common Stock Payment of exercise Dispose F No No 552.77 2,302 1.27M 184,702.53
26 Aug 21 Boxer Michael A Common Stock Payment of exercise Dispose F No No 552.77 240 132.66K 11,078

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

85.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2013 1987 +1.3%
Opened positions 146 139 +5.0%
Closed positions 120 137 -12.4%
Increased positions 827 810 +2.1%
Reduced positions 725 744 -2.6%
13F shares
Current Prev Q Change
Total value 169.44B 153.9B +10.1%
Total shares 335.91M 337.28M -0.4%
Total puts 2.13M 1.73M +23.1%
Total calls 1.96M 2.51M -21.9%
Total put/call ratio 1.1 0.7 +57.7%
Largest owners
Shares Value Change
Vanguard 30.71M $15.49B -0.4%
BLK Blackrock 28.75M $14.51B -1.9%
STT State Street 15.55M $7.85B +2.1%
Capital World Investors 14.77M $7.45B -11.8%
TROW T. Rowe Price 13.32M $6.72B +19.1%
Massachusetts Financial Services 12.03M $6.07B -2.2%
FMR 10.13M $5.11B -15.4%
Capital Research Global Investors 9.06M $4.57B +2.3%
MS Morgan Stanley 8.31M $4.19B +0.2%
Geode Capital Management 6.07M $3.05B +2.9%
Largest transactions
Shares Bought/sold Change
TROW T. Rowe Price 13.32M +2.13M +19.1%
Amundi Pioneer Asset Management 0 -2.13M EXIT
Capital World Investors 14.77M -1.97M -11.8%
FMR 10.13M -1.84M -15.4%
Amundi 1.77M +1.77M NEW
Wellington Management 4.14M -1.03M -19.9%
HBCYF HSBC 1.82M +997.95K +121.6%
IVZ Invesco 1.44M -907.79K -38.6%
Generation Investment Management 1.71M +688.02K +67.6%
Putnam Investments 1.11M +670.37K +152.7%

Financial report summary

?
Management Discussion
  • Sales in the second quarter of 2021 increased $2.36 billion from the second quarter of 2020. Aside from the effects of currency translation and acquisitions, revenues increased $1.92 billion (28%) primarily due to increased demand. Sales of products that address COVID-19 testing and treatment increased $0.58 billion to $1.87 billion in the second quarter of 2021. Conditions were very robust in each of the company’s end markets during the second quarter of 2021 driven by three factors: strong fundamentals in the life sciences, strong economic activity globally and the role the industry is playing in the pandemic response. Sales were particularly strong to academic and government, as well as industrial and applied customers, which were most affected in the second quarter of 2020 due to business disruptions related to the pandemic. Sales to customers in pharma and biotech markets were very strong driven by underlying market dynamics and the company’s role in supporting customers across a wide range of therapeutic areas. Sales to customers in diagnostics and healthcare markets were strong as customer demand for non-COVID-19 response products and services was approaching pre-pandemic levels. Sales growth was strong in each of the company’s primary geographic areas during the second quarter of 2021.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: approaching, behalf, certification, compensatory, copy, digital, document, documentary, duly, embedded, Exhibit, formatted, FTC, furnish, HSR, Inline, instance, Joseph, Label, lessened, Linkbase, merger, playing, proposed, request, Restated, role, Schema, Taxonomy, therapeutic, thereunto, undersigned, waiting, XBRL
Removed: accelerated, continuing, diagnosing, focused, number, past